GOlDilOCS: Genomic determinants of outcome in cardiogenic shock
Research type
Research Study
Full title
Prospective observational study investigating genomic determinants of outcome from cardiogenic shock
IRAS ID
290406
Contact name
Alastair Proudfoot
Contact email
Sponsor organisation
Barts Health NHS Trust
Duration of Study in the UK
4 years, 0 months, 1 days
Research summary
Cardiogenic shock (CS) is a condition in which your heart suddenly can't pump enough blood to meet your body's needs, most often because of a heart attack. About 4 in 10 people with CS die. This has been the case for the last 20 years.
Our understanding of why the body can respond badly to a heart attack is very poor. Current treatments are expensive and not proven to reduce death rates, probably because they don't reverse the underlying problem(s) that lead to death.
We plan to take a new approach to studying CS by analysing genetic data from the blood of patients with CS. We hope that we will be able to:
- better understand the reasons why people develop CS and die from it
- work out which patients are likely to respond to current and new treatments and why
- identify new targets for drug treatmentsREC name
East of England - Essex Research Ethics Committee
REC reference
21/EE/0279
Date of REC Opinion
2 Mar 2022
REC opinion
Further Information Favourable Opinion